These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

12570 related articles for article (PubMed ID: 11848487)

  • 21. In vitro cytotoxic dose-relation of cisplatin and sodium thiosulphate in human tongue and oesophageal squamous carcinoma cell lines.
    Kovács AF; Cinatl J
    J Craniomaxillofac Surg; 2002 Feb; 30(1):54-8. PubMed ID: 12064884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy].
    Takemura M; Osugi H; Lee S; Kaneko M; Tanaka Y; Fujiwara Y; Nishizawa S; Iwasaki H; Higashino M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1399-402. PubMed ID: 15446565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture].
    Miyoshi T; Ogawa S; Kanamori T; Nobuhara M; Kimoto T; Namba M
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2207-11. PubMed ID: 6191694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
    Bazarbashi S; Abdelsalam M; Amin T; El-Bassiouni M; Soudy H; Elweshi A; Alhusseiny H; Rehman K; Memon M; Ajarim D
    Chemotherapy; 2008; 54(4):315-22. PubMed ID: 18701820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
    Hirao M; Fujitani K; Tsujinaka T
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):53-6. PubMed ID: 15675582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
    Okamura M; Hashimoto K; Shimada J; Sakagami H
    Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
    Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
    Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines.
    Schaber B; Mayer P; Schreiner T; Rassner G; Fierlbeck G
    Melanoma Res; 1994 Oct; 4(5):319-26. PubMed ID: 7858417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
    Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined effect of interferons alpha, beta and gamma on tumor growth in vitro].
    Kimoto Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):302-7. PubMed ID: 3080965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
    Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
    Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
    Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
    Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines.
    Koike K; Takaki A; Tatsukawa M; Suzuki M; Shiraha H; Iwasaki Y; Sakaguchi K; Shiratori Y
    Int J Oncol; 2006 Nov; 29(5):1253-61. PubMed ID: 17016659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming growth factor-beta is an endogenous radioresistance factor in the esophageal adenocarcinoma cell line OE-33.
    Kim AH; Lebman DA; Dietz CM; Snyder SR; Eley KW; Chung TD
    Int J Oncol; 2003 Dec; 23(6):1593-9. PubMed ID: 14612931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
    Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
    Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 629.